Toggle navigation
About Us
Overview
Management Team
Press Room
Careers
Contact us
Healthcare Professionals
Overview
Licenses and Certifications
Publications
Billing Information
Investors
Patients
Overview
Breast Cancer
Metastatic Cancer
Glossary
Billing Information
Make a Payment
Products
Order
Physician Portal
Order a Test
Press Room
1
2
3
4
5
6
7
New Data Affirms Value of Breast Cancer Index (BCI) in Identification of Early Stage ER+ Breast Cancer Patients Appropriate for Extended Endocrine Therapy (EET)
Biotheranostics Appoints Don Hardison as New CEO
Biotheranostics Presents First Data from the BCI Clinical Database for Correlative Studies
Breast Cancer Index
SM
(BCI) Included in Updated Guidelines for Use of Clinical Biomarkers in Breast Cancer
Study Demonstrates Use of Breast Cancer Index
SM
(BCI) Leads to Significant Changes in Physician Recommendations for Extended Endocrine Therapy in ER+ Breast Cancer Patients
Study Presented at San Antonio Breast Cancer Symposium Demonstrates Strong Performance of Biotheranostics’ 92-gene Assay in the Diagnosis of Triple Negative Breast Cancer
Breast Cancer Index
SM
Predicted Patients at High Risk of Recurrence Despite Low Risk Clinical Features, New Data Suggest
New Data Substantiate the Ability of Breast Cancer Index
SM
to Help Physicians Identify Early Stage ER+ Breast Cancer Patients for Extended Anti-Estrogen Therapy
Biotheranostics & Syapse Collaborate to Integrate Genomics-Based Molecular Diagnostics for Cancer into the Syapse Precision Medicine Platform
Biotheranostics Appoints Industry Veteran Don Hardison to Board of Directors
Biotheranostics’ Announces New Data Presented at 2016 ASCO Annual Meeting
Study Presented at ASCO 2016 Shows Clinical Utility of Biotheranostics’ CancerTYPE ID® in Predicting Tumor Type & Aiding in Treatment Optimization for Metastatic Cancer Patients
1
2
3
4
5
6
7